Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chadi Hage Chehade

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
Cancer|April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorGeorges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
Cancer|April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorGeorges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
JAMA Network Open|October 2, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 AlterationsMicah Ostrowski, Yeonjung Jo, Chadi Hage Chehade, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Pageof 3